Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluticasone propionate intranasal - OptiNose

Next Previous
Drug Profile

Fluticasone propionate intranasal - OptiNose

Alternative Names: FLU-EDS; OPN-375; Opt-FP; OPTINOSE; OptiNose fluticasone propionate; XHANCE

Latest Information Update: 17 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OptiNose AS
  • Developer OptiNose
  • Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Nasal polyps
  • Phase III Sinusitis
  • No development reported Asthma

Most Recent Events

  • 01 May 2019 Optinose initiates a phase III trial for Sinusitis in USA (NCT03960580)
  • 06 Mar 2019 OptiNose announces intention to seek approval for Sinusitis in USA for Fluticasone propionate intranasal
  • 22 Feb 2019 Optinose completes a phase III trial for Nasal polyps in USA (NCT03591068)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top